Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06360042
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2024-02-27
Brief Title:
Anti-PD-1PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
Anti-PD-1PD-L1 Combined With Anti-angiogenic Agents as First-line Therapy for Unresectable Hepatocellular Carcinoma a Multicenter Randomized Open-label Trial
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter randomized open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib cohort 1 or Adebrelimab plus Bevacizumab cohort 2 or Camrelizumab plus Apatinib cohort 3 as first-line treatment of unresectable HCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None